TABLE 2.

Pooled RR and relative CrI of 50% response rates, 75% response rates, and serious adverse events derived from network meta-analysis with different treatment regimens in patients with migraine.

Intervention	50% response rates	75% response rates	Serious adverse events
Compared with placebo
Eptinezumab	1.40 [0.97, 2.02]	1.59 [1.15, 2.20]	1.25 [0.49, 3.35]
Erenumab	1.75 [1.30, 2.44]	–	1.15 [0.57, 2.39]
Fremanezumab	2.29 [1.63, 3.25]	3.23 [1.52, 7.36]	1.16 [0.52, 2.88]
Galcanezumab	1.53 [1.18, 1.99]	2.14 [1.69, 2.95]	2.95 [1.41, 6.87]
Compared with eptinezumab
Erenumab	1.25 [0.78, 2.07]	–	0.91 [0.27, 3.02]
Fremanezumab	1.65 [1.00, 2.75]	2.04 [0.89, 4.96]	0.94 [0.27, 3.42]
Galcanezumab	1.09 [0.70, 1.73]	1.35 [0.91, 2.15]	2.38 [0.70, 8.65]
Compared with erenumab
Fremanezumab	1.30 [0.82, 2.05]	–	1.00 [0.34, 3.25]
Galcanezumab	0.88 [0.58, 1.29]	–	2.56 [0.93, 7.84]
Compared with fremanezumab
Galcanezumab	0.67 [0.43, 1.03]	0.67 [0.28, 1.52]	2.54 [0.80, 7.95]

RR: relative risk; CrI: credibility interval.